Related by context. All words. (Click for frequent words.) 69 alvespimycin 67 pertuzumab 66 ZACTIMA 66 deforolimus 66 oral ridaforolimus 65 neratinib 65 forodesine 65 evaluating tivozanib 65 Quinamed 65 Tarceva TM 64 CYT# potent vascular disrupting 64 Bayer HealthCare Onyx Pharmaceuticals 64 HGS# 64 LHRH receptor positive 64 Ixempra 64 acyclovir Lauriad R 64 phase Ib 64 assessing T DM1 64 receptor tyrosine kinase inhibitor 64 Avastin adjuvant 64 Ophena TM 64 metastatic colorectal 63 HER2 positive metastatic breast 63 BR.# 63 randomized Phase IIb 63 relapsed MM 63 enzastaurin 63 ospemifene 63 ixabepilone 63 lintuzumab 63 IMA# 63 Phase 1b trial 63 Phase Ib IIa clinical 63 oral deforolimus 63 evaluating mipomersen 63 docetaxel Taxotere R 63 EGFR mutation positive 63 afatinib 63 galiximab 63 MAGE A3 ASCI 62 regorafenib 62 Pertuzumab 62 ToGA 62 Allovectin 7 62 multicenter Phase II 62 FOLFOX6 chemotherapy regimen 62 commercialize deforolimus 62 pain palliation 62 cilengitide 62 refractory metastatic 62 erlotinib Tarceva ® 62 rALLy clinical trial 62 Phase #b/#a clinical 62 demonstrated antitumor activity 62 NP2 Enkephalin 62 YONDELIS 62 advanced metastatic renal 62 Afatinib 62 IIa trial 62 axitinib 62 TORISEL TM 62 ACTEMRA TM 62 Phase Ib II 62 cediranib 62 Cloretazine 62 constipation OIC 62 ELACYT 62 refractory indolent non 62 kidney urologic 62 BRIM2 62 BCIRG 62 sorafenib tablets 61 INSPIRE Trial Phase III 61 evaluating Actimmune 61 Vicinium TM 61 ThermoDox ® clinical 61 PI3K/Akt pathway inhibitor 61 ZOLINZA 61 EOquin TM 61 BrachySil TM 61 randomized Phase III 61 farletuzumab 61 registrational trial 61 paclitaxel cisplatin 61 BRIM3 61 neoadjuvant treatment 61 tubulin inhibitor 61 ThermoDox R 61 relapsed SCLC 61 Aplidin 61 BRAF inhibitor 61 lintuzumab SGN 61 trastuzumab DM1 T DM1 61 Teriflunomide 61 refractory chronic lymphocytic 61 NSABP 61 Zemplar Capsules 61 lung pancreatic 61 Ceflatonin 61 FOLOTYN ® 61 including eniluracil ADH 61 Tarvacin Anti Cancer 61 motesanib 61 sunitinib Sutent 61 Phase IIIb clinical 61 Xelox 61 progressive metastatic prostate 61 double blinded randomized 61 BCR ABL inhibitor 61 Allovectin 7 ® 61 ® bortezomib 60 ovarian endometrial 60 trastuzumab DM1 60 vemurafenib 60 CTAP# Capsules 60 thetreatment 60 XL# SAR# 60 phase IIb clinical 60 HuMax EGFr 60 plus dacarbazine 60 APTIVUS 60 recurrent metastatic 60 phase IIb study 60 dirucotide MBP# 60 MGd 60 OncoVex 60 GVAX ® 60 Hepatocellular Carcinoma HCC 60 severe hypercholesterolemia 60 CARE HF 60 stage IIIB IV 60 elotuzumab 60 Proellex TM 60 Enzastaurin 60 R sorafenib tablets 60 reslizumab 60 cisplatin gemcitabine 60 orally inhaled migraine 60 Phase Ib clinical 60 null responder 60 thalidomide Thalomid 60 AKT inhibitor 60 dimebon latrepirdine 60 #I TM# 60 gefitinib Iressa 60 antiretroviral naïve 60 biliary tract cancer 60 Tykerb lapatinib 60 Myocet 60 CIMZIA TM certolizumab pegol 60 immunotherapeutic approaches 60 PKC# 60 bavituximab monotherapy trial 60 ChronVac C R 60 Phase IIb III 60 confirmatory clinical 60 SUCCEED trial 60 immune modulating 60 CINQUIL 60 blinded randomized placebo controlled 60 paclitaxel poliglumex 60 registrational Phase 60 IL# PE#QQR 60 HGS ETR2 60 lenalidomide Revlimid R 60 recurrent metastatic ovarian cancer 60 riociguat 60 TNFerade TM 60 recurrent glioblastoma multiforme 60 RSD# oral 60 APPRAISE 60 Panzem R NCD 60 phase IIa clinical 60 relapsed multiple myeloma 60 Femara letrozole 60 sorafenib Nexavar 60 fosbretabulin 60 recurrent glioblastoma 59 unresectable tumors 59 AML MDS 59 AVAiL 59 oncolytic virus therapies 59 BioNumerik 59 metastatic pancreatic 59 placebo controlled Phase III 59 LUX Lung 59 CRLX# 59 pelvic malignancies 59 Novolimus 59 Phase #/#a trial 59 eribulin mesylate 59 advanced medullary thyroid 59 HuLuc# 59 Edge STudy 59 aflibercept VEGF Trap 59 paclitaxel Taxol R 59 pharmacogenomic translational research 59 EndoTAGTM 1 59 metastatic gastric 59 Evoltra ® 59 castrate resistant prostate cancer 59 relapsed refractory multiple myeloma 59 IMiDs ® compound 59 Canvaxin TM 59 radiolabeled TM# 59 immunotherapeutic vaccine 59 sunitinib malate 59 Curaxin CBLC# 59 VADT 59 TTF Therapy 59 novel VDA molecule 59 relapsing remitting MS RRMS 59 vidofludimus 59 ongoing Phase 1b 59 Virulizin ® 59 oxymorphone ER 59 eritoran 59 ZD# [001] 59 NCCTG 59 Fludara ® 59 deCODE ProstateCancer TM 59 epigenetic therapies 59 OvaRex 59 entinostat 59 DEB# 59 recombinant PSMA vaccine 59 placebo controlled clinical 59 develop HBV reactivation 59 LymphoStat B belimumab 59 YONDELIS R 59 evaluating satraplatin 59 hypoxia activated prodrug 59 Group RTOG 59 follicular lymphoma FL 59 squamous cell lung cancer 59 number NCT# ClinicalTrials.gov 59 Sudhir Agrawal D.Phil 59 Revlimid lenalidomide 59 opioid naive 59 Aflibercept 59 Cloretazine ® 59 GRNVAC1 59 SWOG 59 Cloretazine R VNP#M 59 Immunotherapeutic 59 ZFP Therapeutics 59 recurrent malignant glioma 59 Genasense ® 59 sapacitabine CYC# 59 metastatic HRPC 59 Tyrima 59 AVN# Phase 59 IRESSA 59 ticagrelor Brilinta 59 colorectal bladder 59 TMC# C# 59 OHR/AVR# 59 visilizumab 59 papillary renal cell carcinoma 59 unresectable stage 59 Phase IIIb 58 advanced unresectable 58 multitargeted 58 TransVax ™ 58 huC# DM4 58 myelodysplastic myeloproliferative diseases 58 unique alkylating agent 58 DCVax R 58 tolevamer 58 Rituxan rituximab 58 paclitaxel Taxol ® 58 Zoraxel 58 SUTENT ® 58 gemcitabine Gemzar ® 58 gastro intestinal inflammation 58 antiangiogenic therapy 58 phase IIa 58 metaglidasen 58 Tanespimycin 58 sarcoma melanoma 58 oral picoplatin 58 phase IIb trial 58 tanespimycin 58 ORENCIA R 58 castration resistant hormone refractory 58 GRN# 58 metastatic ocular 58 midstage clinical 58 personalized cellular immunotherapy 58 AEG# 58 treatment naive genotype 58 stage IIIb IV 58 GW# [003] 58 pharmacokinetic PK study 58 AGILECT R 58 Phase 1a clinical 58 phase IIb 58 metastatic androgen independent 58 antibody MAb 58 catheter occlusion 58 HERCEPTIN 58 vaccines oncolytic virus 58 dacetuzumab 58 multicenter Phase 58 Phase 2a trial 58 albiglutide 58 colorectal lung 58 samalizumab 58 previously untreated follicular 58 phase IIb III 58 CBLC# 58 GEM OS2 58 ocrelizumab 58 advanced hepatocellular carcinoma 58 KRN# 58 PEG SN# 58 Elotuzumab 58 MCSP respectively 58 ALK inhibitors 58 IMiDs R 58 NeuroFlo 58 SinuNase TM 58 medically inoperable 58 budesonide MMX Phase III 58 docetaxel Taxotere ® 58 ACRIN 58 lymphomas leukemias 58 OvaRex ® MAb 58 OMP #R# 58 IAP inhibitors 58 PRECISE Trial 58 Bowel Project NSABP 58 ® natalizumab 58 CCR9 antagonist 58 fostamatinib 58 EchoCRT 58 PDE# inhibitors 58 PRESEPT 58 oral prodrug 58 radiation chemoradiation 58 Clinical Antipsychotic Trials 58 Diamyd ® 58 coinfected patients 58 evaluating REVLIMID 58 temsirolimus 58 evaluating picoplatin 58 Benlysta belimumab 58 olaparib 58 RESOLUTE clinical 58 Phase #b/#a 58 vinca alkaloid 58 novel chimeric natriuretic 58 GVAX Pancreas Vaccine 58 heavily pretreated 58 concurrent chemoradiation 58 Roche Xeloda 58 paclitaxel Taxol 58 aripiprazole Abilify 58 PSMA ADC 58 temsirolimus Torisel ® 58 BARACLUDE ® 58 chronic thromboembolic pulmonary 58 adecatumumab MT# 58 multicenter randomized controlled 58 Neoadjuvant 58 Mycophenolate Mofetil 58 NATRECOR R 58 pioglitazone hydrochloride 58 Group NCIC CTG 58 metastatic GIST 58 ZYBRESTAT fosbretabulin 58 colorectal ovarian 58 oral ghrelin agonist 58 figitumumab 58 HCV SPRINT 58 multiple myeloma MM 58 telomerase inhibitor drug 58 treatment naïve genotype 58 Phase 1b clinical trials 58 certolizumab 58 lorvotuzumab mertansine 58 rALLy 58 elacytarabine 58 subcutaneous formulation 58 Alessandro Riva 58 CALGB 58 Onrigin 58 TLK# 58 Troxatyl 58 ganetespib 58 HCD# [002] 57 interferon gamma 1b 57 Simulect 57 refractory acute myeloid 57 Deforolimus 57 known sulfonamide allergy 57 tarenflurbil 57 palifosfamide 57 Vitaxin 57 KRAS mutations occur 57 infliximab Remicade 57 Pemetrexed 57 brivaracetam 57 CHAMPION PCI 57 Crofelemer budesonide foam 57 EDEMA3 57 Amrubicin 57 bevacizumab Avastin 57 Ozarelix 57 Prospective Randomized 57 CR# vcMMAE 57 Alequel 57 decitabine 57 Perforomist ™ Inhalation Solution 57 trastuzumab Herceptin R 57 Velcade bortezomib 57 COU AA 57 TELINTRA 57 ACTIVE W 57 neoadjuvant 57 GAMMAGARD 57 candidates Dyloject TM 57 standard chemotherapy regimen 57 essential thrombocythemia ET 57 patientswith 57 EOquin TM phase 57 TEMSO 57 MKC# MT 57 ORENCIA ® 57 ErbB2 positive 57 NO# [002] 57 zanolimumab 57 maximally tolerated lipid lowering 57 CURE AF 57 PF # [002] 57 Trastuzumab DM1 57 humanised monoclonal antibody 57 HRPC ovarian cancer 57 SUSTENNA TM 57 Phase IIb clinical trials 57 docetaxel chemotherapy 57 novel therapeutic antibodies 57 APEX PD 57 pralatrexate injection folate analogue 57 adecatumumab 57 trabectedin 57 Panzem NCD 57 ASA# 57 Elacytarabine 57 PRESEPT study 57 CYP#D# inhibitor 57 ZACTIMA TM ZD# 57 gastrointestinal stromal 57 Aryplase 57 investigational protease inhibitor 57 selective angiogenic kinase inhibitor 57 rindopepimut 57 nonmetastatic 57 tremelimumab 57 BRAF mutated 57 RGB # 57 MabThera rituximab 57 TO AVOID PREGNANCY WHILE 57 squamous histology 57 HER2 positive cancers 57 telomerase therapeutic 57 confirmatory Phase III 57 tramiprosate Alzhemed TM 57 cardio renal 57 TORISEL 57 Irinotecan 57 cisplatin chemotherapy 57 Zybrestat 57 RoACTEMRA 57 ritonavir boosted danoprevir 57 Phase 2b clinical 57 isoform selective 57 Dacogen injection 57 drug figitumumab 57 Platinol ® cisplatin 57 adalimumab Humira 57 velafermin 57 Hormone Refractory Prostate Cancer 57 R#/MEM # 57 plus prednisone prednisolone 57 prokinetic agent 57 PANVAC VF 57 estramustine 57 PrevOnco ™ 57 XIENCE V Stent System 57 Tesmilifene 57 BOLDER II 57 personalized immunotherapy 57 nilotinib Tasigna 57 brivanib 57 Neulasta ® 57 TASKi2 57 anti angiogenic therapy 57 investigational therapies 57 Panzem R 57 clinicaltrials 57 AVOREN 57 clinical trials Archexin 57 alfa 2a 57 LungAlert TM 57 bortezomib Velcade R 57 IMC #B 57 Targretin capsules 57 Phase IIa trials 57 Taxotere ® 57 SNT MC# 57 Onconase 57 AVADO 57 Motesanib 57 selective modulator 57 Hedgehog antagonist 57 AA Amyloidosis 57 StemEx R 57 HGS ETR1 57 drug Treanda 57 INCB# [001] 57 null responder HCV 57 Cloretazine R 57 Nexavar sorafenib 57 TRISENOX 57 AAG geldanamycin analog 57 minimally symptomatic 57 Phase Ib 57 double blinded placebo 57 Rheos System 57 oral antiviral 57 nonsmall cell lung cancer 57 OvaRex R 57 hormone receptor negative 57 multicenter dose escalation 57 gemcitabine carboplatin 57 PRT# 57 Exherin TM 57 GOUT 57 briakinumab 57 differentiated thyroid 57 Annamycin 57 Triapine R 57 metastatic kidney 57 Capesaris 57 CIPN 57 epoetin alpha 57 CAMMS# 57 initiated Phase Ib 57 Taxotere docetaxel 57 ONCONASE R 57 pazopanib 57 HIV coinfected 56 tamoxifen Nolvadex ® 56 Phase 2b study 56 Phase 1b clinical 56 NABTT 56 recurrent glioma 56 anastrozole Arimidex 56 JAK inhibitor 56 Xanafide 56 pancreatic prostate 56 Pirfenidone 56 pharmacokinetic pharmacodynamic 56 huN# DM1 56 novel oral anticoagulant 56 registrational 56 Allovectin 7 R 56 ABSORB trial 56 bardoxolone methyl 56 multicenter phase 56 investigational monoclonal antibody 56 HQK 56 Campath alemtuzumab 56 rALLy trial 56 PLX MS 56 Hodgkin lymphoma HL 56 Nicole Onetto MD 56 EXPLORE Xa 56 next generation URAT1 56 RE LY 56 clevidipine 56 leukotriene receptor antagonist 56 PROSTVAC TM 56 oral talactoferrin 56 rituximab refractory 56 ENESTnd 56 GLP toxicology studies 56 PRIMO CABG 56 subcutaneous PRO 56 Archexin 56 exemestane Aromasin 56 GVAX R 56 diabetic neuropathic pain 56 PORxin TM platforms 56 deCODE AF TM 56 Panzem ® 56 Phase 1b 56 UVIDEM 56 oral FTY# 56 Certolizumab pegol 56 Phase Ib clinical trials 56 placebo controlled Phase 56 deep venous thromboses 56 Glufosfamide 56 Group B CALGB 56 oral JAK#/JAK# inhibitor 56 BRCA deficient 56 teriflunomide 56 LEUKINE 56 crizotinib PF # 56 diseases fat malabsorption 56 BioSante LibiGel Phase III 56 torsemide ER 56 RELOVAIR ™ 56 BAY #-# 56 smoldering multiple myeloma 56 Prodarsan R 56 HGS ETR1 mapatumumab 56 Gynecologic Oncology Group 56 antiarrhythmic drug 56 liver metastasis 56 LCP AtorFen 56 Phase IIb trials 56 goserelin 56 phase IIIb 56 PrevOnco 56 viral kinetics 56 erlotinib Tarceva 56 cutaneous T cell 56 Manja Bouman CEO 56 ASCEND HF 56 CINTREDEKIN BESUDOTOX 56 Carotid Revascularization Endarterectomy vs. 56 Renal Cell Carcinoma RCC 56 initiate Phase Ib 56 candidate CRLX# 56 plus COPEGUS 56 Pyridorin 56 OVATURE 56 metastatic renal cell carcinoma 56 mapatumumab 56 predictive biomarkers 56 BCG refractory 56 PEG PAL 56 Budesonide foam crofelemer 56 chemotherapy hormonal therapy 56 Phase 2a clinical 56 radezolid 56 nonnucleoside reverse transcriptase inhibitors 56 GMX# 56 tumor histology 56 herpetic keratitis 56 HYVET 56 EVEREST II 56 raloxifene Evista 56 relapsing multiple sclerosis 56 nephrology oncology 56 treating cancerous tumors 56 custirsen 56 SILENOR 56 Lenocta 56 Testosterone MDTS ® 56 APTIVUS R 56 NCCN guidelines 56 Telik logo TELINTRA 56 p# inhibitor 56 eosinophilic asthma 56 Denufosol 56 glycosylated hemoglobin levels 56 leukemia multiple myeloma 56 IIa clinical trials 56 Gleevec imatinib 56 Oral NKTR 56 invasive lobular carcinoma 56 initiate Phase 2b 56 uric acid lowering 56 cangrelor 56 NATRECOR ® 56 Xcellerated T Cells 56 Evaluation Program CTEP 56 ALN HTT 56 randomized Phase 2b 56 mRCC 56 cell lymphoma CTCL 56 talactoferrin 56 Panzem 56 cisplatin vinorelbine 56 prospective multicentre 56 Azacitidine 56 Trofex 56 Provectus Pharmaceuticals specializes 56 R entecavir 56 haematological cancers 56 CoFactor 56 IMC A# 56 MEND CABG II 56 chemotherapy cisplatin 56 Azedra 56 multicenter Phase III 56 CALGB # [002] 56 DNA methyltransferase inhibitors 56 Brentuximab Vedotin SGN 56 TACI Ig 56 HORIZONS AMI 56 OMP #M# 56 pegylated liposomal doxorubicin 56 irinotecan chemotherapy 56 midstage trials 56 INS# [001] 55 LibiGel ® 55 Colon polyps 55 LAB CGRP 55 pharmacogenetic testing 55 ongoing Phase IIIb 55 aldosterone antagonists 55 landmark ATHENA 55 LEVADEX ™ 55 JAK2 inhibitor 55 FASLODEX 55 CIMZIA ™ 55 Ophena 55 prospective nonrandomized 55 anti PlGF 55 COMFORT II 55 Trimesta 55 PLX STROKE targeting 55 Multicenter Automatic Defibrillator Implantation 55 Folfox 55 celgosivir 55 Degarelix 55 MyVax personalized immunotherapy 55 SinuNase ™ 55 antihormonal 55 oral methylnaltrexone 55 microwave hyperthermia 55 Fabry Disease 55 vandetanib 55 Entereg R 55 recombinant biopharmaceutical 55 pivotal bioequivalence 55 Sebivo 55 metastatic sarcomas 55 trastuzumab emtansine T DM1 55 CLORETAZINE TM VNP#M 55 psoriatic arthritis PsA 55 CHARISMA trial 55 MEND CABG 55 Phase IIIb study 55 Prostate Lung Colorectal 55 Her2 positive 55 PHX# 55 CLARITY study 55 talabostat 55 denileukin diftitox 55 Canvaxin 55 PXD# 55 anthracycline taxane 55 AE# vaccine 55 rheumatoid arthritis inflammatory bowel 55 mTOR kinase 55 Bicifadine 55 beta blockers ACE inhibitors 55 Ceplene/IL-2 55 CDAD Clostridium difficile 55 recurrent ovarian cancer 55 pomalidomide 55 adult chronic ITP 55 Clonicel 55 Curaxin 55 Syncria albiglutide 55 recurrent herpes labialis 55 fusion enhancers 55 rNAPc2 55 Pivotal Phase 55 GLPG# 55 EDEMA3 trial 55 fallopian tube carcinoma 55 chemotherapy docetaxel 55 torezolid phosphate 55 refractory CLL 55 clinical trials SGN 55 budesonide foam 55 Pagoclone 55 GALNS 55 Egrifta 55 tenofovir emtricitabine 55 Dr. Kandzari 55 Neulasta R 55 histologies 55 CRMD# 55 via intradermal injections 55 Nothing Wadden 55 UPLYSO 55 Atrasentan 55 ACOSOG Z# 55 Lixivaptan 55 Phase 2b trial 55 onset AF 55 oral PTH 55 NSABP B 55 Tramiprosate ALZHEMED TM 55 stage IIIb 55 motesanib diphosphate 55 RhuDex 55 Phase IIb clinical 55 lexidronam injection 55 Smac mimetics 55 Gefitinib 55 antiangiogenesis therapies 55 ENDEAVOR IV 55 Factor VIIa 55 molecularly targeted therapy 55 cMET 55 ADVANCE PD 55 EGEN 55 intensive lipid lowering 55 Epirubicin 55 Soliris TM eculizumab 55 heparin induced thrombocytopenia 55 Insulin PH# 55 cathepsin K inhibitor 55 POSIDUR TM 55 sipuleucel T 55 albiglutide currently 55 Mipomersen 55 produces radioisotopes 55 refractory CTCL 55 CCX# B 55 EmbraceAC 55 ENMD # 55 castration resistant prostate cancer 55 phase III ACCLAIM 55 opioid naïve 55 testing huN# DM1 55 Flu Cy 55 pan HDAC inhibitor 55 oral anticancer 55 targeted radiotherapeutics 55 IIa clinical 55 ExTRACT TIMI 55 dose escalation clinical 55 depsipeptide 55 Squalamine 55 evaluating carfilzomib 55 Carfilzomib 55 targeting miR 55 leading oral taxane 55 Amigal 55 squalamine 55 Sorafenib HCC Assessment 55 ADAGIO study 55 oxypurinol 55 hormonally sensitive 55 ascending dose 55 MERLIN TIMI 55 MGN# 55 beta carotene supplementation 55 AVONEX ® 55 senicapoc 55 efaproxiral 55 ARRY # 55 receiving chemoradiation therapy 55 RRMS patients 55 Subgroup analysis 55 GI motility disorders 55 gastrointestinal stromal tumor GIST 55 anti angiogenic agents 55 carboplatin paclitaxel 55 multicenter placebo controlled 55 mTOR inhibitor 55 vosaroxin 55 darinaparsin Zinapar TM 55 targeted radiotherapeutic 55 HER2 amplified 55 Neuradiab TM 55 panobinostat 55 TBC M4 55 abacavir lamivudine 55 dose escalation trial 55 REMINYL ® 55 Solazed 55 immunotherapeutic agent 55 CD# CEA 55 administered intranasally 55 allogeneic HSCT 55 BZA CE 55 standard chemotherapy regimens 55 adjuvant radiotherapy 55 IIb clinical trial 55 iniparib 55 subgroup analyzes 55 multicenter prospective 55 multicenter randomized placebo controlled 55 CIMZIA TM 55 lumiliximab 55 CDK cyclin dependent 55 immunomodulatory agents 55 ovarian suppression 55 statin cholesterol lowering 55 lung cancer NSCLC 55 humanized interleukin 6 55 novel antimitotic agent 55 8mg/kg 55 JAK inhibitors 55 dose escalation phase 54 refractory NSCLC 54 im peramivir 54 Blinatumomab 54 metastatic neuroendocrine tumors 54 potent suppressor 54 RE LY ® 54 metastatic malignant 54 granted Ortec 54 dose escalation Phase 54 cancer mCRC 54 vivo preclinical 54 indiplon capsules 54 refractory gastrointestinal stromal 54 prospective observational studies 54 nab paclitaxel 54 Combo Stent 54 insulin glulisine 54 MEK inhibitors 54 ASG 5ME 54 MEK inhibitor RDEA# 54 unstable angina UA 54 incyclinide 54 Phase 2b clinical trials 54 treating neuropathic pain 54 CTA# Injection 54 Voraxaze ™ 54 CYT# novel 54 intravesical infusion therapy 54 Glioblastoma Multiforme GBM 54 MDS AML 54 Steven R. Deitcher 54 SYMMETRY SM trial 54 sodium thiosulfate STS 54 PREZISTA r 54 PhG alpha 1 54 metastatic RCC 54 GSK# [001] 54 pemetrexed 54 pharmacodynamic PD 54 obatoclax 54 Plicera 54 placebo controlled dose escalation 54 DDP# 54 balsalazide tablet 54 investigational HCV polymerase 54 Zolinza 54 Instanyl 54 Ocrelizumab 54 ORACLE MS 54 Heterozygous Familial Hypercholesterolemia 54 inhibit platelet function 54 myelofibrosis polycythemia vera 54 endothelin antagonists 54 relapsed leukemia 54 aromatase inhibitors AIs 54 EGFR mutation status 54 urocortin 2 54 Alocrest 54 external counterpulsation systems 54 oncology radiation oncology 54 subcutaneous methylnaltrexone 54 REVIVE Diabetes 54 THALOMID 54 Edurant 54 orally administered inhibitor 54 histologically confirmed 54 potentially hepatotoxic 54 OvaRex MAb 54 Cell Lymphoma CTCL 54 Val HeFT 54 Intravenous CP 54 Initiates Enrollment 54 BEXXAR 54 concurrent ITP 54 patients undergoing percutaneous 54 protein tyrosine phosphatase 1B 54 malignant mesothelioma Alfacell 54 trastuzumab Herceptin ® 54 completely resected 54 BCX# 54 Exelixis XL# 54 Proxinium TM 54 Fx #A 54 EFAPROXYN 54 HER2 positive breast 54 ganaxolone 54 solid tumors ZYBRESTAT 54 dexanabinol 54 novel tubulin binding 54 gastrointestinal stromal tumors GIST 54 recurrent GBM 54 Urocidin 54 abiraterone acetate